UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 18, 2011
ADVANCED LIFE SCIENCES HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-51436 |
|
30-0296543 |
|
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
1440 Davey Road |
|
|
|
Woodridge, Illinois |
|
60517 |
|
(Address of principal executive offices) |
|
(Zip Code) |
(630) 739-6744
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On April 18, 2011, Dr. Michael T. Flavin, Chairman and Chief Executive Officer of Advanced Life Sciences Holdings, Inc. (the “Company”), advanced to the Company $63,000 in cash in order to assist the Company in satisfying certain working capital obligations. The Company intends to repay this advance to Dr. Flavin as soon as reasonably practicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ADVANCED LIFE SCIENCES HOLDINGS, INC. | |
|
|
|
|
|
|
|
|
|
Dated: April 22, 2011 |
By: |
/s/ Michael T. Flavin |
|
|
Name: |
Michael T. Flavin, Ph.D. |
|
|
Title: |
Chairman and Chief Executive Officer |